151 related articles for article (PubMed ID: 10756122)
1. Altered cardiac endothelin receptors and protein kinase C in deoxycorticosterone-salt hypertensive rats.
Fareh J; Touyz RM; Schiffrin EL; Thibault G
J Mol Cell Cardiol; 2000 Apr; 32(4):665-76. PubMed ID: 10756122
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the endothelin ET(B) receptor in gender differences in deoxycorticosterone acetate-salt-induced hypertension.
Kawanishi H; Hasegawa Y; Nakano D; Ohkita M; Takaoka M; Ohno Y; Matsumura Y
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):280-5. PubMed ID: 17324138
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of endothelin-1 gene may cause blood pressure-independent vascular hypertrophy.
Schiffrin EL; Larivière R; Li JS; Sventek P; Touyz RM
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S5-8. PubMed ID: 8587458
[TBL] [Abstract][Full Text] [Related]
4. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats.
Fareh J; Touyz RM; Schiffrin EL; Thibault G
Hypertension; 1997 Nov; 30(5):1253-9. PubMed ID: 9369284
[TBL] [Abstract][Full Text] [Related]
5. Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy.
Wolf SC; Amend T; Risler T; Amann K; Brehm BR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():276S-279S. PubMed ID: 12193103
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms.
Callera GE; Tostes RC; Yogi A; Montezano AC; Touyz RM
Clin Sci (Lond); 2006 Feb; 110(2):243-53. PubMed ID: 16271043
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-1 signaling is altered in cardiac cells from deoxycorticosterone acetate-salt hypertensive rats.
Touyz RM; Fareh J; Thibault G; Schiffrin EL
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S179-81. PubMed ID: 9595432
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of endothelin B receptors in kidneys of DOCA-salt hypertensive rats.
Pollock DM; Allcock GH; Krishnan A; Dayton BD; Pollock JS
Am J Physiol Renal Physiol; 2000 Feb; 278(2):F279-86. PubMed ID: 10662732
[TBL] [Abstract][Full Text] [Related]
9. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism.
Ammarguellat F; Larouche I; Schiffrin EL
Circulation; 2001 Jan; 103(2):319-24. PubMed ID: 11208696
[TBL] [Abstract][Full Text] [Related]
10. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
12. Cardiac microvasculature in DOCA-salt hypertensive rats : effect of endothelin ET(A) receptor antagonism.
Larouche I; Schiffrin EL
Hypertension; 1999 Oct; 34(4 Pt 2):795-801. PubMed ID: 10523363
[TBL] [Abstract][Full Text] [Related]
13. Involvement of endothelin-1 in deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy.
Matsumura Y; Fujita K; Miyazaki Y; Takaoka M; Morimoto S
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S456-8. PubMed ID: 8587444
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Hypertens Res; 2010 Mar; 33(3):255-62. PubMed ID: 20057489
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats.
Wang DS; Xie HH; Shen FM; Cai GJ; Su DF
Clin Exp Pharmacol Physiol; 2005 Jul; 32(7):545-52. PubMed ID: 16026514
[TBL] [Abstract][Full Text] [Related]
16. Role of endothelin and vasopressin in DOCA-salt hypertension.
Yu M; Gopalakrishnan V; McNeill JR
Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
[TBL] [Abstract][Full Text] [Related]
17. Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats.
Matsumura Y; Kuro T; Konishi F; Takaoka M; Gariepy CE; Yanagisawa M
Br J Pharmacol; 2000 Mar; 129(6):1060-2. PubMed ID: 10725252
[TBL] [Abstract][Full Text] [Related]
18. Decreased endothelin binding and [Ca2+]i signaling in microvessels of DOCA-salt hypertensive rats.
Molero MM; Giulumian AD; Reddy VB; Ludwig LM; Pollock JS; Pollock DM; Rusch NJ; Fuchs LC
J Hypertens; 2002 Sep; 20(9):1799-805. PubMed ID: 12195122
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.
Watts SW; Fink GD; Northcott CA; Galligan JJ
Br J Pharmacol; 2002 Sep; 137(1):69-79. PubMed ID: 12183332
[TBL] [Abstract][Full Text] [Related]
20. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
Carneiro FS; Nunes KP; Giachini FR; Lima VV; Carneiro ZN; Nogueira EF; Leite R; Ergul A; Rainey WE; Clinton Webb R; Tostes RC
J Sex Med; 2008 Dec; 5(12):2793-807. PubMed ID: 18823320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
